Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


US FDA Creates Expedited Review For Military-Related Products

Executive Summary

All 'top priority' battlefield products will get FDA review by June 30; longer term plan includes draft guidance on development of products designed for use in austere conditions.

You may also be interested in...

Warp Speed May Be Usurping BARDA, Potentially Hurting COVID-19 Vaccine Prospects

Congress wants HHS to explain why BARDA scientists were removed from leadership positions on COVID-19 vaccine contracts. It is just one of multiple examples of Democrats raising concerns that Operation Warp Speed could be hurting, not helping the COVID-19 response effort.

Gottlieb On Being Senate-Confirmed US FDA Commissioner: It's Certainly An Advantage

US FDA would have more influence in inter-agency turf battles, can build stronger relationships on Capitol Hill with a confirmed commissioner, Scott Gottlieb says.

Dsuvia Approval May Be Followed By New Opioid Review Paradigm At FDA

US FDA Commissioner Gottlieb defended the decision to clear the controversial opioid in the agency’s press release on the approval, and announced a possible shift in how future opioid applications are reviewed.  

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts